EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...
A recent study reveals the pivotal role of tristetraprolin (TTP), an RNA-binding protein, in regulating inflammatory responses in basophils, immune cells central to allergic reactions. The research ...
GI-102 is under clinical development by GI Innovation and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...